Clinical trial establishes
Whatever your specialty, one of the all-around high- lights of Saturday’s live programme and perhaps of the whole congress will be the EULAR Recommen- dations 2020 highlight session on 6 June.
During the session you can expect to hear quick-fire and practical reprises of recently or soon-to-be published EULAR recommendations, such as those on the management of RA, psoriaticarthritis (PsA), and rheumatic immune-related adverse events(irAEs) associated with cancer immunotherapy.
You can also be one of the first to hear about draft guidanceon new points to consider for the management of intra-articulartherapy and lifestyle recommendations to prevent the progression of rheumatic and musculoskeletal diseases (RMDs).
And that’s not all, there will beother EULAR recommendations/points to consider presented on howto integrate patients’ perspectivesinto patient-reported outcomes measures, on how to interpret antinucle-ar antibody tests, and on how to usework participation as an outcomemeasure in clinical studies, with twofinal abstract presentations.
First up at the virtual podium will be Prof. Josef S. Smolen ofthe Medical University of Vienna to present “2019 update ofthe EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifyingantirheumatic drugs” (DMARDs). These were recently published(Ann Rheum Dis. 2020;79:685-99) so you can expect to hear aconcise summary of the key points covered by the revised recommendations.
The 2019 update is based on the best available scientific
eularcongressnews.comFriday/Saturday 5/6 June
An authorised publication of the European League Against Rheumatism
Tight control (TC) and treat-to-target (T2T) proved more beneficial than did usual care (UC) as treatment strat- egies for patients with axial spondyloarthritis (axSpA), according to the results of a first-of-its-kind internationalclinical trial.
This trial, known as Tight Control in Spondyloarthritis (TICOSPA), comes on the heels of previous trials evaluating T2T andTC in rheumatoid arthritis and psoriatic arthritis. Where the TICOSPA trial differs, however, is that the investigators sought tocompare strategies of care in the field of axSpA and determinetheir distinct benefits.
“Unlike previous T2T trials in rheumatology, we decided to
run a study where the target was different than the main out-
come,” lead author Dr. Anna Moltó of the department of rheu-
matology at Cochin Hospital in Paris, said in an interview. She
will discuss the group’s findings today in a presentation entitled
“Treat-to-target in axSpA: does it work?”
Their findings are also the subject of an award-winning ab
Continued on page 3 Continued on page 6